Multivalent tau and Aβ vaccine on SNAP liposomes for Alzheimer’s disease
Official title: Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes
Funded at Pop Biotechnologies, INC · NIH-11418521 · Data updated 2026-11-12
A new vaccine approach aims to train the immune system to target multiple Alzheimer’s disease proteins at once, potentially slowing or preventing progression in people at risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 15, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $822,289 |
| NIH project number | 5R42AG082620-04 |
| Project ID | NIH-11418521 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals at risk for or diagnosed with Alzheimer’s disease or related dementias, who could participate in future clinical development stages or contribute samples.
✕Less likely to help
Patients without access to a future trial or those not yet eligible for immunotherapy may not benefit directly.
What this research studies
This project focuses on creating a mosaic vaccine (SNAP-AD) that presents several disease-related targets on tiny liposome particles to stimulate a stronger immune response. It builds on prior work showing that hitting multiple epitopes of Aβ and tau may be more effective than targeting a single site. The study will scale up production, develop quality controls, and prepare for potential clinical development. Although the work started in mice and early-stage models, it is designed with future human trials in mind and uses a platform intended to be translatable to patients. The grant funds collaboration between a biotech company and researchers to advance toward an IND.
Why it matters
Potential benefit: If successful, this approach could lead to a more effective immunotherapy for Alzheimer's disease, potentially slowing cognitive decline.
How similar studies have gone: Prior single-epitope immunotherapies have shown limited success; this study is novel in its multiepitope strategy, with promising preclinical milestones.
Where this research is happening
-
Pop Biotechnologies, INC
Buffalo, United States Active
Researchers
- Principal investigator: Huang, Wei-Chiao — Pop Biotechnologies, INC
- Study coordinator: Huang, Wei-Chiao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.